Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

1.140 -0.060 (-5.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
RenovoRx Engages Oklahoma University (OU) Health as First Clinical Site in Preparation for the Pivotal Phase III CouGar Clinical Trial in Bile Duct Cancer
From RenovoRx, Inc.
Via Business Wire
RenovoRx Announces Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting
From RenovoRx, Inc.
Via Business Wire
Biopharma Company Issues New Patent Application Adding to Strong IP Portfolio of 9 Patents Issued and 9 Pending; Phase 3 Clinical Trials for Cancer Treatments in Collaboration with Imugene: RenovoRx (NASDAQ: RNXT) $RNXT
Via Viz Release
Topics Intellectual Property
Recap: RenovoRx Q3 Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
RenovoRx Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
From RenovoRx, Inc.
Via Business Wire
Biopharma Company Reaches Phase 3 Clinical Trials for Cancer Treatments; 9 Patents Issued; Collaboration with Imugene: RenovoRx (NASDAQ: RNXT)
Via Get News
Topics Intellectual Property
RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023
From RenovoRx, Inc.
Via Business Wire
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
From RenovoRx, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference
From RenovoRx, Inc.
Via Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
Via Get News
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
From RenovoRx, Inc.
Via Business Wire
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
--News Direct-- 
Via News Direct
RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform
 
Via TheNewswire.com
RenovoRx, Inc. Stock Presents A Compelling Value Proposition After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
Via AB Newswire
Topics Death
RenovoRx, Inc. Stock Surges After Reporting Positive Data From Its Phase III TIGeR-PaC Trial ($RNXT)
Via AB Newswire
Topics Death
Why RenovoRx Stock Is Moving Today
RenovoRx, Inc. (NASDAQ: RNXT) shares are trading higher Thursday after the company released interim data on progression-free survival from Phase 3 open label TIGeR-PaC study of RenovoGem 
Via Benzinga
Microcap Biotech Stock RenovoRx is Shooting Higher Today: Here's Why
RenovoRx Inc (NASDAQ: RNXT) presented new data on progression-free survival (PFS) from the pivotal Phase 3 open-label TIGeR-PaC study of RenovoGem (intra-arterial administration of gemcitabine) in... 
Via Benzinga
Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Sigilon Therapeutics, Inc. (NASDAQ: SGTX) shares climbed 523.8% to $24.25 after Eli Lilly agreed to acquire the company for $14.92/share in cash. 
Via Benzinga
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform 
Via News Direct
RenovoRx encountering "a lot of enthusiasm" for innovative cancer platform
RenovoRx Inc (NASDAQ:RNXT) CEO Shaun Bagai speaks to Thomas Warner during a visit to Europe to present at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) in Barcelona. Bagai gives an... 
Via TheNewswire.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
From RenovoRx, Inc.
Via Business Wire
Catalyst Watch: RenovoRx, Inc. Stock Jumps 14% Ahead of Thursday’s Phase III TIGeR-PaC Trial Update ($RNXT)
Via AB Newswire
Topics Death
Catalyst Watch: RenovoRx, Inc. Nears June 29th Data Release From Its Phase III TIGeR-PaC Trial Targeting Pancreatic Cancer ($RNXT)
Via AB Newswire
Topics Death
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.